The 20 Best Cutaneous T-Cell Lymphoma (CTCL) Doctors Near Me in Ann Arbor, MI

Dr. Tejasvi received his medical degree from Karnataka Institute of Medical Sciences, India. He completed residency-training program and worked as senior resident in Dermatology and Venereology, from All India Institute of Medical Sciences, New Delhi, India. He completed post-doctoral training in genetics of psoriasis under the direction of Drs. R.P.Nair and James T. Elder at the University of Michigan, Department of Dermatology in Ann Arbor.Dr. Tejasvi's primary research interest is translational genetics, epigenetics in psoriasis and pharmacogenetics that involves application of genetic information to predict response to therapies. Dr. Tejasvi is rated as an Elite provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). He is also highly rated in 39 other conditions, according to our data. His clinical expertise encompasses Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, and Lymphomatoid Papulosis.

The T-cell lymphomas are a heterogeneous and poorly understood group of non-Hodgkin’s lymphomas. The most common T-cell lymphoma in the United States includes a heterogeneous mix of lymphomas that lack distinguishing characteristics and, until recently, remained clinically and molecularly “unspecified”. Improved understanding of T-cell lymphoma pathogenesis and the development of novel therapeutic strategies will be needed to address this challenge and improve outcomes for patients afflicted with these aggressive lymphomas. My group made the landmark discovery that the most common T-cell lymphoma in North America is comprised of two molecularly and clinically distinct subsets. This finding has significant implications for the classification and treatment of these lymphomas. We have also demonstrated that malignant T cells remain dependent upon antigen-presenting cells within the tumor microenvironment and are developing novel therapeutic strategies targeting these cells. Many fundamental questions, including the “cell of origin”, the role of antigen-, costimulatory-, and cytokine-receptor signaling, and the contribution of myeloid-derived antigen-presenting cells in disease pathogenesis remain obscure. My laboratory uses complementary mouse models and primary T-cell lymphoma specimens (in ex vivo and patient-derived xenograft studies) to address these fundamental and clinically relevant questions. We are poised to clinically translate our laboratory-based findings into novel therapeutic strategies that we hope will improve outcomes for patients afflicted with these aggressive lymphomas. I enjoy working with a multidisciplinary team of enthusiastic collaborators who share this common goal. Dr. Wilcox is rated as an Elite provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Wilcox is board certified in Internal Medicine, Hematology, and Medical Oncology.

Dr. Lauren Smith received her undergraduate degree at the University of Michigan Honors College with highest distinction in 1992. She spent four years working in a neurogenetics laboratory at the University of San Francisco with Dr. Nelson Freimer. For the next two years she worked as a manuscript editor for Dr. Donald Klein, a psychiatrist, at Columbia University. In 1998, she began medical school at the University of Michigan. She was awarded AOA in her junior year and was president of the UM AOA Chapter the following year. She completed her residency in anatomic/clinical pathology and fellowship in hematopathology from 2002-2007. In July, 2007 she began her faculty career as an Assistant Professor at the University of Michigan and was promoted to Associate Professor in 2013. She was appointed Fellowship Director in 2013. She was appointed the Director of the Ethics Path of Excellence in the University of Michigan Medical School in 2013. She became the permanent Director of the Hematopathology Section in 2016. In addition, she serves as a Hospital Ethicist at UMHS. Dr. Smith is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). She is also highly rated in 29 other conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, T-Cell Lymphoma, Peripheral T-Cell Lymphoma, and Angioimmunoblastic T-cell Lymphoma.

Dr. Allison Billi is an assistant professor in the University of Michigan Department of Dermatology. Her research aims to define how the skin contributes to systemic autoimmune disease through identifying female-biased pathways and factors in skin that are critical to autoimmunity. In addition, she provides medical dermatology care to patients of all ages within our outpatient clinic at Domino’s Farms.Dr. Billi is a graduate of the University of Michigan Medical School where she received her medical degree and her PhD in Human Genetics. Following graduation, she completed her transitional year at Beaumont Hospital in Dearborn, Michigan, and a dermatology residency and post-doctoral research fellowship at the University of Michigan Department of Dermatology. Dr. Billi is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). She is also highly rated in 21 other conditions, according to our data. Her clinical expertise encompasses Cutaneous Lupus Erythematosus (CLE), Psoriasis, Lichen Planus, and Actinic Keratosis. Dr. Billi is board certified in Dermatology.

John Runge is a Dermatologist practicing medicine in Ann Arbor, Michigan. Dr. Runge is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). He is also highly rated in 1 other condition, according to our data. His clinical expertise encompasses Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Sezary Syndrome, and Lymphomatoid Papulosis.

Alexandra Hristov is a Hematologist and a Dermatologist practicing medicine in Ann Arbor, Michigan. Dr. Hristov is rated as a Distinguished provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, T-Cell Lymphoma, and Sezary Syndrome. Dr. Hristov is board certified in Dermatopathology, Pathology-Anatomic/Pathology-Clinical, and Hematopathology.

Mark Kaminski is an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Kaminski is rated as a Distinguished provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Gastric Lymphoma, and Bone Marrow Aspiration.

Dr. Kelly Harms, MD, PhD, is a faculty member in the Department of Dermatology at the University of Michigan and the director of our Multi-disciplinary Cutaneous Oncology clinic. She provides patient care in our Cutaneous Surgery and Oncology clinical programs, including the Mohs surgery clinic and multidisciplinary melanoma and cutaneous oncology clinics located within the U-M Rogel Cancer Center. Dr. Harms is a board-certified dermatologist and ACGME Fellowship-trained Mohs Surgeon, with specialized training and expertise in treating high-risk skin cancer.Dr. Harms joined the Dermatology faculty in 2014, upon completing her ACGME procedural dermatology fellowship, with advanced training in melanoma and cutaneous surgery and oncology at the Rogel Cancer Center. Her clinical work is focused on Mohs surgery and associated reconstruction, as well as the complex management of patients seen within our Multidisciplinary Melanoma and Merkel Cell Programs.Dr. Harms received her medical degree from the University of Alabama School of Medicine and her Ph.D. degree from the Medical Scientist Training Program in the Department of Cell Biology at the University of Alabama at Birmingham. She completed her internship in the Department of Internal Medicine, University of Michigan Hospitals. She completed her dermatology residency, post-doctoral research training, and procedural dermatology fellowship in the Department of Dermatology, University of Michigan Medical School. Her clinical research is focused on skin cancer biology and epidemiology, and therapy. Dr. Harms is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Merkel Cell Carcinoma, Melanoma, Eccrine Porocarcinoma, and Basal Cell Skin Cancer. Dr. Harms is board certified in Dermatology and Micrographic Dermatologic Surgery.

Dr. Cuneo grew up in Northern California. He studied Biological and Environmental Engineering at Cornell University in Ithaca, NY. Dr. Cuneo received his Doctor of Medicine degree from Vanderbilt University School of Medicine in 2007 and completed an internship there in 2008. In 2008 he started his residency in Radiation Oncology at Duke University Medical Center. Dr. Cuneo has been an Assistant Professor in the Department of Radiation Oncology at the University of Michigan since 2012. Dr. Cuneo is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). He is also highly rated in 35 other conditions, according to our data. His clinical expertise encompasses Anal Cancer, Pancreatic Cancer, Liposarcoma, Liver Cancer, and Pancreaticoduodenectomy. Dr. Cuneo is board certified in Radiation Oncology.

Dr. Carty completed her undergraduate work at Harvard University, graduating magna cum laude, with a degree in Biochemical Sciences. She attended the Albert Einstein College of Medicine in New York where she earned her MD degree. Dr. Carty stayed in New York for her internal medicine residency at Columbia University Medical Center, and moved to the Hospital of the University of Pennsylvania for her Hematology-Oncology fellowship. She remained on staff at the Hospital of the University of Pennsylvania before moving here to Ann Arbor. Dr. Carty is the recipient of a K08 Award for her work in T cell biology and ASH Scholar Award for her research on T cell lymphomas. Dr. Carty is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). She is also highly rated in 21 other conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Large-Cell Immunoblastic Lymphoma, and Bone Marrow Aspiration. Dr. Carty is board certified in Hematology.

After receiving my M.D. and Ph.D. at the University of Alabama at Birmingham, I came to the University of Michigan for residency training in Anatomic Pathology. During my residency and subsequent Dermatopathology fellowship, I became interested in mechanistic studies of cutaneous and soft-tissue malignancies. Upon completion of my fellowship in June 2012, I accepted a faculty position at UMHS with joint appointments in the Departments of Dermatology and Pathology, in which I continue to investigate molecular events in the pathogenesis of Merkel cell carcinoma and other cutaneous malignancies, while maintaining clinical effort in dermatopathology and molecular dermatopathology. Dr. Harms is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Merkel Cell Carcinoma, Tieche-Jadassohn Nevus, Melanoma, and Sebaceous Adenoma. Dr. Harms is board certified in Pathology-Anatomic and Dermatopathology.

Dr. May Chan obtained her medical degree from the State University of New York at Buffalo and was a Howard Hughes Research Scholar in 2005-2006. She completed residency training in Anatomic Pathology at Beth Israel Deaconess Medical Center in Boston, followed by a Dermatopathology fellowship at Harvard. She joined the University of Michigan in 2011 and is now a Professor of Pathology and Dermatology. She is the Interim Section Head for Dermatopathology, the Program Director for the Dermatopathology Fellowship, and the Medical Director of the Immunohistochemistry Laboratory. She also serves on the Test Development and Advisory Committee of the American Board of Pathology.Dr. Chan is an editorial board member of Modern Pathology and Journal of Cutaneous Pathology. She has a broad research interest in the areas of inflammatory skin diseases, melanocytic lesions, cutaneous adnexal neoplasms, and immunohistochemistry. She is the author/co-author of over 90 peer-reviewed publications and the book, Handbook of Direct Immunofluorescence: A Pattern-based Approach to Skin and Mucosal Biopsies.Dr. Chan is board certified in Anatomic Pathology and Dermatopathology. In addition to her primary role as a dermatopathologist, Dr. Chan retains her interest in surgical pathology including interpretation of head and neck, soft tissue, pulmonary, and endocrine cases, as well as intraoperative frozen sections. Over the years she has been invited to speak at national and international meetings hosted by the United States and Canadian Academy of Pathology (USCAP), the American Society of Dermatopathology (ASDP), the College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), the American Academy of Dermatology (AAD), the European Nail Society, and Dermpedia. Dr. Chan is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Melanoma, Basal Cell Skin Cancer, Sebaceous Adenoma, and Squamous Cell Skin Carcinoma.

Dr. Lowe received her undergraduate degree from Occidental College, Los Angeles, California in 1981 and her M.D. degree from the University of Texas Medical School at Houston, Houston, Texas in 1985. She did a transitional internship at St. Joseph's Hospital, Houston, Texas from 1985-1986 and then was a Post-doctoral Fellow in the Department of Dermatology at the University of Texas Medical School at Houston. From 1987-1989, she completed her residency training in dermatology at the University of Texas Medical School at Houston, followed by a Dermatopathology Fellowship at the University of Colorado School of Medicine, Denver, Colorado, from 1990-1991. Dr. Lowe is board certified in both Dermatology and Dermatopathology.In 1990, Dr. Lowe served as an Instructor in the Department of Dermatology at the University of Texas Medical School at Houston, Houston, Texas. She moved to the Department of Dermatology at Henry Ford Hospital, Detroit, Michigan, where she was a Senior Staff Physician and Director of Dermatopathology from 1991-1996. In 1996 she joined the faculty of the Departments of Pathology and Dermatology at the University of Michigan Medical School, Ann Arbor, Michigan, as Assistant Professor, where she was promoted to Associate Professor in 1998, and to Professor in 2004. She served as the Director of Dermatopathology in the Department of Pathology from 1996-2012.While at the University of Michigan Medical School, Dr. Lowe has been actively involved in the dermatopathology service, teaching and academic pursuits. She has been recognized institutionally and nationally as an educator and clinician. In 2013, Dr. Lowe received the Walter Nickel Teaching Award given by the American Society of Dermatopathology and also received the Outstanding Clinician of the Year Award bestowed by the University of Michigan Medical School. In 2015, she was inducted into the University of Michigan League of Clinical Excellence. Dr. Lowe received the William B. Taylor Resident Teaching Award from the Department of Dermatology, University of Michigan in 1999 and 2005 for exemplary teaching. She has been recognized annually since 2003 in America's Top Doctors for Cancer by Castle Connolly Medical Ltd. She has served on national committees, including the American Board of Dermatology, Dermatopathology Test Committee and the American Board of Pathology, Dermatopathology Test Committee and has served on the editorial boards of both the Journal of the American Academy of Dermatology and Cancer. Dr. Lowe is the author or co-author of more than 130 publications in peer-reviewed journals. Dr. Lowe is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). She is also highly rated in 21 other conditions, according to our data. Her clinical expertise encompasses Melanoma, Sebaceous Adenoma, Syringoma, and Syringocystadenoma Papilliferum. Dr. Lowe is board certified in Dermatology and Dermatopathology.

Mari Castanedo is a Dermatologist practicing medicine in Ann Arbor, Michigan. Dr. Castanedo is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses Actinic Keratosis, Warts, Psoriasis, and Melanoma.

Dr. Frank Wang, MD is a board-certified Dermatologist. He graduated from Stanford University and received his medical degree from Cornell University Medical College. Dr. Wang served his internship at the University of Pittsburgh Medical Center, and went on to complete a Fellowship and his Dermatology Residency here at the University of Michigan. In 2010, Dr. Wang joined the faculty at the University of Michigan Department of Dermatology. His interests and expertise include general clinical dermatology, and clinical and basic science research in the area of skin aging. Dr. Wang is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). He is also highly rated in 57 other conditions, according to our data. His clinical expertise encompasses Psoriasis, Actinic Keratosis, Pyoderma Gangrenosum, and Melanoma. Dr. Wang is board certified in Dermatology.

Johann Gudjonsson, MD, PhD is the Arthur C. Curtis Professor of Molecular Skin Immunology and the Frances and Kenneth Eisenberg Emerging Scholar of the Taubman Medical Research Institute. A graduate of the University of Iceland Medical School, he completed his internship and dermatology residency training at the University of Michigan. Dr. Gudjonsson has served on the faculty of the University of Michigan Department of Dermatology since 2008. He provides general medical dermatology patient care at the University of Michigan Taubman Center and maintains clinical and research interests in inflammatory and autoimmune disorders involving the skin.Dr. Gudjonsson came to the U-M in 2003 as part of an innovative research residency training program. Building upon investigative dermatology training completed in Iceland, Dr. Gudjonsson has been performing basic immunological and genetic work on psoriasis at the U-M. Dr. Gudjonsson's primary research focus is basic immunological and genetic research on psoriasis, with projects directed at improving the diagnosis and treatment of psoriasis. He received the 2007 Young Investigator Award from the American Academy of Dermatology, was named the 2018 Rising Star Lecturer for the Society for Investigative Dermatology and was recipient of the American Skin Association Research Achievement Award in Psoriasis in 2021. Dr. Gudjonsson's research has been supported by research awards from the National Institutes of Health (NIH), the American Skin Association, Dermatology Foundation, Doris Duke Foundation, among others. Dr. Gudjonsson is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). He is also highly rated in 39 other conditions, according to our data. His clinical expertise encompasses Psoriasis, Darier Disease, Benign Chronic Pemphigus, Cutaneous Lupus Erythematosus (CLE), and Vitrectomy. Dr. Gudjonsson is board certified in Dermatology.

Elizabeth Spratt is a Dermatologist practicing medicine in Ann Arbor, Michigan. Dr. Spratt is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). She is also highly rated in 31 other conditions, according to our data. Her clinical expertise encompasses Actinic Keratosis, Melanoma, Giant Congenital Melanocytic Nevus, and Giant Congenital Nevus.

Terri Bott-Kothari, MD has been in practice for over 16 years treating all disease sites. She completed her medical training at Wayne State University School of Medicine and residency at the University of Cincinnati. Dr. Bott is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Pleuropulmonary Blastoma, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Familial Prostate Cancer. Dr. Bott is board certified in Radiation Oncology.

John Maciejewski is a Hematologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Maciejewski is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Multiple Myeloma, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Burke joined the faculty in July 2014. He attended Providence College in Rhode Island where he earned his BS in Biology. Subsequently, he matriculated at the Icahn School of Medicine at Mount Sinai and earned his MD. He then completed a residency in Internal Medicine at the University of Chicago Medical Center, followed by a year serving as a Chief Resident. He recently completed his Hematology/Medical Oncology fellowship at Memorial Sloan Kettering Cancer Center in New York where his clinical and research interests focused on leukemia, particularly adult acute lymphoblastic leukemia (ALL). He performed clinical research regarding the role of asparaginase and “pediatric-inspired” therapeutic regimens in adult ALL, as well as investigating therapies that spare cytotoxic chemotherapy in older adult Philadelphia chromosome-positive ALL. Dr. Burke is focused on early phase clinical trials in acute leukemias and is treating patients with hematologic malignancies. Dr. Burke is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Aplastic Anemia, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Burke is board certified in Hematology and Medical Oncology.